Research Article Details
| Article ID: | A26618 |
| PMID: | 20085121 |
| Source: | Eur Rev Med Pharmacol Sci |
| Title: | Relationship of insulin resistance and adipocytokines on serum alanine aminotransferase in presurgical morbid obese patients. |
| Abstract: | BACKGROUND AND OBJECTIVE: Insulin resistance and adipocytokines have been associated with fat liver and non-alcoholic fat liver disease (NAFLD). The aim of this research was to study the influence of insulin resistance and adipocytokines in presurgical morbid obese patients on elevated serum alanine aminotransferase (ALT) as an indicator of NAFLD. SUBJECTS AND METHODS: A population of 65 presurgical morbid obese patients was analyzed in a cross sectional study. HOMA-IR was calculated as indicator of insulin resistance. Adipocytokines (leptin, resistin, adiponectin, Interleukin-6 and TNF alpha) blood levels were measured. RESULTS: Patients were classified as group I (n=33) when serum ALT activity was normal or group II (NAFLD patients; n=32) when serum ALT activity was greater than the median value of the group (> or =24 UI/L). In NAFLD group, BMI, weight, fat mass, waist to hip ratio, waist circumference, HOMA and insulin levels were higher than control group. Adiponectin levels were lower in group II than I. Anthropometric parameters were higher in both groups. In the multivariate analysis with dietary intake-, age- and sex-adjusted ALT concentration as a dependent variable, only HOMA remained as an independent predictor in the model (F=12.1; p<0.05). ALT concentration increased 0.48 UI/L (CI95%: 0.19-0.76) for each unit of HOMA increased. CONCLUSION: Anthropometric parameters and insulin resistance are associated with elevated serum alanine aminotransferase in obese morbid patients with lower levels of adiponectin. However, in a multiple regression model only insulin resistance remained in the model. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D199 | L-alanine | Chemical drug | DB00160 | KYNU | -- | Failed in clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D094 | Cysteamine | Chemical drug | DB00847 | GSS stimulant | Renal drug | Under clinical trials | Details |
| D095 | Cysteamine bitartrate | Chemical drug | DB00847 | -- | -- | Under clinical trials | Details |